Table 4:

Relative probabilities of guideline-directed therapies, comparing young (34–54-year-old) women and men presenting with acute myocardial infarction. The Atherosclerosis Risk in Communities Surveillance Study, 1995–2014.

	Women vs. Men (ref.): Relative Probabilities*				Trend‡
Therapy	1995–1999	2000–2004	2005–2009	2010–2014	P-value
Aspirin	0.96 (0.86 – 1.02)	0.98 (0.90 – 1.04)	1.02 (0.93 – 1.06)	0.96 (0.86 – 1.03)	0.8
Non-Aspirin Antiplatelet†	---	0.95 (0.83 – 1.06)	0.75 (0.61 – 0.89)	0.79 (0.65 – 0.94)	0.3
Lipid Lowering Agent†	---	1.01 (0.89 – 1.11)	0.86 (0.72 – 0.98)	0.80 (0.67 – 0.91)	0.005
Beta Blocker	0.94 (0.83 – 1.04)	1.00 (0.92 – 1.06)	0.98 (0.89 – 1.04)	0.92 (0.81 – 0.99)	0.2
Invasive Angiography	0.94 (0.82 – 1.06)	0.95 (0.84 – 1.06)	0.91 (0.76 – 1.05)	0.88 (0.73 – 1.03)	0.3
Revascularization	0.97 (0.81 – 1.14)	0.88 (0.74 – 1.02)	0.63 (0.49 – 0.79)	0.72 (0.56 – 0.88)	0.002

^*Models adjusted for race (black or white), geographic location (Forsyth County, NC; Jackson, MS; Minneapolis, MN; or Washington County, MD), and year of hospital admission.

^†Non-aspirin antiplatelets not routinely abstracted prior to 1996. Lipid lowering agents not routinely abstracted prior to 1998.

^‡Management trends over time assessed by testing the multiplicative interaction between sex and time, adjusted for race, geographic location, and year of admission